{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:30:13Z","timestamp":1793637013941,"version":"4.5.1"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.neo.2026.101375","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:01:26Z","timestamp":1791428486000},"page":"101375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Engineering CAR-T cell therapies for digestive tract cancer: advances, challenges, and strategies to overcome tumor heterogeneity and immunosuppressive barriers"],"prefix":"10.1016","volume":"82","author":[{"given":"Qiaoyan","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neo.2026.101375_bib0001","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.neo.2026.101375_bib0002","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12935-025-03938-0","article-title":"Advancements and challenges in CAR-T cell therapy for solid tumors: a comprehensive review of antigen targets, strategies, and future directions","volume":"25","author":"Zhu","year":"2025","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.neo.2026.101375_bib0003","article-title":"Current state of CAR-T cell therapies for solid tumors","volume":"7","author":"Rosa","year":"2026","journal-title":"Medicine"},{"key":"10.1016\/j.neo.2026.101375_bib0004","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.neo.2026.101375_bib0005","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.trecan.2025.08.009","article-title":"Overcoming solid-tumor barriers: armored CAR-T cell therapy","volume":"11","author":"Kwon","year":"2025","journal-title":"Trends. Cancer"},{"key":"10.1016\/j.neo.2026.101375_bib0006","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41392-024-02097-4","article-title":"Digestive cancers: mechanisms, therapeutics and management","volume":"10","author":"Zhan","year":"2025","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.neo.2026.101375_bib0007","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2026.101375_bib0008","article-title":"Harnessing NKG2D CAR-T cells with radiotherapy: a novel approach for esophageal squamous cell carcinoma treatment","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2026.101375_bib0009","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.neo.2026.101375_bib0010","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.1158\/1078-0432.CCR-24-1853","article-title":"Preclinical evaluation of AZD6422, an armored chimeric antigen receptor T cell targeting CLDN18.2 in gastric, pancreatic, and esophageal cancers","volume":"30","author":"Barrett","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101375_bib0011","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41419-025-07905-5","article-title":"ULBP2 CAR-T cells enhance gastric cancer immunotherapy by inhibiting CAF activation","volume":"16","author":"Zhang","year":"2025","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.neo.2026.101375_bib0012","doi-asserted-by":"crossref","first-page":"29","DOI":"10.25259\/Cytojournal_245_2024","article-title":"Enhanced efficacy of dual chimeric antigen receptor-T cells targeting programmed death-ligand 1 and cancer-associated fibroblasts in colorectal cancer in vitro","volume":"22","author":"Gao","year":"2025","journal-title":"Cytojournal"},{"key":"10.1016\/j.neo.2026.101375_bib0013","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-022-00385-1","article-title":"Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy","volume":"10","author":"Cao","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.neo.2026.101375_bib0014","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s12275-024-00133-0","article-title":"Genetically engineered CLDN18.2 CAR-T cells expressing synthetic PD1\/CD28 fusion receptors produced using a lentiviral vector","volume":"62","author":"Lee","year":"2024","journal-title":"J. Microbiol."},{"key":"10.1016\/j.neo.2026.101375_bib0015","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1158\/1535-7163.MCT-25-0171","article-title":"Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity","volume":"25","author":"Du","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.neo.2026.101375_bib0016","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.3390\/cancers16234052","article-title":"Carcinoembryonic antigen expression in Human tumors: a tissue microarray study on 13,725 tumors","volume":"16","author":"Jansen","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2026.101375_bib0017","article-title":"Development of CAR-T cell persistence in adoptive immunotherapy of solid tumors","volume":"10","author":"Fan","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.neo.2026.101375_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114083","article-title":"PD1-TLR10 fusion protein enhances the antitumor efficacy of CAR-T cells in colon cancer","volume":"148","author":"Peng","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.neo.2026.101375_bib0019","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1158\/2326-6066.CIR-24-0137","article-title":"Nanobody-directed CEA-targeting CAR T cells eliminate gastrointestinal cancer xenografts","volume":"13","author":"Feng","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.neo.2026.101375_bib0020","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s43018-026-01124-3","article-title":"Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial","volume":"7","author":"Gao","year":"2026","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.neo.2026.101375_bib0021","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.neo.2026.101375_bib0022","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101375_bib0023","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neo.2026.101375_bib0024","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/ITT.S507522","article-title":"Tumor immunotherapy targeting B7-H3: from mechanisms to clinical applications","volume":"Volume 14","author":"Guo","year":"2025","journal-title":"Immunotargets. Ther."},{"key":"10.1016\/j.neo.2026.101375_bib0025","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12935-022-02471-8","article-title":"Antitumor responses in gastric cancer by targeting B7H3 via chimeric antigen receptor T cells","volume":"22","author":"Sun","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.neo.2026.101375_bib0026","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41416-025-03114-1","article-title":"The pronounced cytotoxic effects of chimeric antigen receptor T cells targeting B7-H3 in organoids and liver xenografts derived from colorectal cancer patients","volume":"133","author":"Sheng","year":"2025","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.neo.2026.101375_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216303","article-title":"A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma","volume":"568","author":"Wang","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.neo.2026.101375_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101138","article-title":"Targeting CD276 by CAR-T cells induces regression of esophagus squamous cell carcinoma in xenograft mouse models","volume":"14","author":"Xuan","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.neo.2026.101375_bib0029","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1158\/1078-0432.CCR-25-4600","article-title":"Allogeneic B7-H3-targeted CAR V\u03b41T-cell therapy in advanced solid tumors: a phase I study","volume":"32","author":"Liu","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101375_bib0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.15698\/cst2019.06.188","article-title":"Biology and clinical relevance of EpCAM","volume":"3","author":"Keller","year":"2019","journal-title":"Cell Stress."},{"key":"10.1016\/j.neo.2026.101375_bib0031","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12876-024-03286-9","article-title":"Chimeric antigen receptor-T cells targeting epithelial cell adhesion molecule antigens are effective in the treatment of colorectal cancer","volume":"24","author":"Zeng","year":"2024","journal-title":"BMC. Gastroenterol."},{"key":"10.1016\/j.neo.2026.101375_bib0032","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1016\/j.ymthe.2025.08.014","article-title":"Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer","volume":"33","author":"Fang","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.neo.2026.101375_bib0033","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jamaoncol.2024.3891","article-title":"Chimeric antigen receptor T cells targeting CD19 and GCC in metastatic colorectal cancer: a nonrandomized clinical trial","volume":"10","author":"Chen","year":"2024","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.neo.2026.101375_bib0034","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/JCO-25-01090","article-title":"Guanylyl Cyclase 2C-targeted chimeric antigen receptor T-cell therapy in patients with metastatic colorectal cancer","volume":"44","author":"Qi","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2026.101375_bib0035","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00262-008-0635-x","article-title":"TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors","volume":"58","author":"Maccalli","year":"2009","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.neo.2026.101375_bib0036","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1158\/1078-0432.CCR-17-1766","article-title":"NKG2D-Dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma","volume":"24","author":"Weiss","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101375_bib0037","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.3390\/cancers17193186","article-title":"A novel early memory-enriched allogeneic NKG2D CAR-T cell therapy based on CRISPR\/Cas9 technology for solid tumors","volume":"17","author":"Aparicio","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2026.101375_bib0038","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s13402-025-01066-5","article-title":"Synthetic NKG2D receptor (SNR) armored CAR-T cells overcome antigen heterogeneity of solid tumor","volume":"48","author":"Sun","year":"2025","journal-title":"Cell Oncol."},{"key":"10.1016\/j.neo.2026.101375_bib0039","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 Testing and Clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.neo.2026.101375_bib0040","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/0300891620960223","article-title":"Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer","volume":"107","author":"Yu","year":"2021","journal-title":"Tumori"},{"key":"10.1016\/j.neo.2026.101375_bib0041","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/s41419-021-04100-0","article-title":"HER2-specific chimeric antigen receptor-T cells for targeted therapy of metastatic colorectal cancer","volume":"12","author":"Xu","year":"2021","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.neo.2026.101375_bib0042","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3390\/cancers17071118","article-title":"Mesothelin as a signal pathways and epigenetic target in cancer therapy","volume":"17","author":"Kumari","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2026.101375_bib0043","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.omto.2021.02.013","article-title":"The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Ther. Oncolytics."},{"key":"10.1016\/j.neo.2026.101375_bib0044","article-title":"Human hyaluronidase PH20 potentiates the antitumor activities of Mesothelin-specific CAR-T cells against gastric cancer","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2026.101375_bib0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00262-024-03909-w","article-title":"CCR5 and IL-12 co-expression in CAR T cells improves antitumor efficacy by reprogramming tumor microenvironment in solid tumors","volume":"74","author":"Tian","year":"2025","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.neo.2026.101375_bib0046","doi-asserted-by":"crossref","first-page":"312","DOI":"10.21037\/jgo-24-25","article-title":"Regional delivery of mesothelin-targeted chimeric antigen receptor T-cell effectively and safely targets colorectal cancer liver metastases in mice","volume":"15","author":"Zhou","year":"2024","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.neo.2026.101375_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155379","article-title":"c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy","volume":"128","author":"Mohan","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.neo.2026.101375_bib0048","doi-asserted-by":"crossref","DOI":"10.1177\/15330338251336850","article-title":"Bispecific c-met\/PD-1 CAR-T cells have enhanced therapeutic effects on solid tumor","volume":"24","author":"Yang","year":"2025","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.neo.2026.101375_bib0049","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1901434","article-title":"Construction of PD1\/CD28 chimeric-switch receptor enhances anti-tumor ability of c-met CAR-T in gastric cancer","volume":"10","author":"Chen","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.neo.2026.101375_bib0050","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.3390\/cancers13225738","article-title":"c-met-specific chimeric antigen receptor T cells demonstrate anti-tumor effect in c-met positive gastric cancer","volume":"13","author":"Kang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2026.101375_bib0051","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s13046-022-02479-y","article-title":"Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy","volume":"41","author":"Chiriaco","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101375_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101575","article-title":"CD166-specific CAR-T cells potently target colorectal cancer cells","volume":"27","author":"He","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.neo.2026.101375_bib0053","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s10238-022-00967-1","article-title":"CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer","volume":"23","author":"Li","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.neo.2026.101375_bib0054","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adr1928","article-title":"Systemic delivery of cadherin 17-specific CAR T cells allows effective and safe targeting of colorectal cancer liver metastases","volume":"17","author":"Greco","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neo.2026.101375_bib0055","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1038\/s41467-023-41338-y","article-title":"Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2 \u00d7 7","volume":"14","author":"Bandara","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2026.101375_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113713","article-title":"SLC7A11-specific CAR-T cell therapy potently targets colorectal and pancreatic cancer","volume":"28","author":"Pan","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.neo.2026.101375_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110402","article-title":"The onco-embryonic antigen ROR1 is a target of chimeric antigen T cells for colorectal cancer","volume":"121","author":"Meng","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.neo.2026.101375_bib0058","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/s41388-025-03322-2","article-title":"Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers","volume":"44","author":"Zhang","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2026.101375_bib0059","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/cells12081139","article-title":"TGF\u03b2 and the tumor microenvironment in colorectal cancer","volume":"12","author":"Waldner","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.neo.2026.101375_bib0060","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting tgf\u03b2-insensitive armored CAR T\u2009cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2026.101375_bib0061","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell."},{"key":"10.1016\/j.neo.2026.101375_bib0062","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1038\/s41388-024-03080-7","article-title":"Tumor-resident microbiota contributes to colorectal cancer liver metastasis by lactylation and immune modulation","volume":"43","author":"Gu","year":"2024","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2026.101375_bib0063","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.18632\/aging.203914","article-title":"Fusobacterium nucleatum promotes liver metastasis in colorectal cancer by regulating the hepatic immune niche and altering gut microbiota","volume":"14","author":"Yin","year":"2022","journal-title":"Aging"},{"key":"10.1016\/j.neo.2026.101375_bib0064","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1158\/2767-9764.CRC-23-0212","article-title":"Peritumoral immune-suppressive mechanisms impede intratumoral lymphocyte infiltration into colorectal cancer liver versus lung metastases","volume":"3","author":"Ye","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.neo.2026.101375_bib0065","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/imm.13642","article-title":"T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it","volume":"169","author":"Yin","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.neo.2026.101375_bib0066","doi-asserted-by":"crossref","first-page":"1","DOI":"10.20892\/j.issn.2095-3941.2024.0628","article-title":"The mechanisms and clinical significance of CD8(+) T cell exhaustion in anti-tumor immunity","volume":"22","author":"Zhong","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.neo.2026.101375_bib0067","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1703394","article-title":"Prognostic significance of hematological parameters and albumin in BCMA-targeted CAR-T therapy for multiple myeloma","volume":"16","author":"Jiang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2026.101375_bib0068","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.eng.2018.12.003","article-title":"Quality control and nonclinical research on CAR-T cell products: general principles and key issues","volume":"5","author":"Li","year":"2019","journal-title":"Engineering"},{"key":"10.1016\/j.neo.2026.101375_bib0069","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s43018-025-00905-6","article-title":"FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy","volume":"6","author":"Ni","year":"2025","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.neo.2026.101375_bib0070","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional Mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the Anti-PD-1 agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.neo.2026.101375_bib0071","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","article-title":"IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases","volume":"42","author":"Zhao","year":"2024","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neo.2026.101375_bib0072","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3390\/ijms19020403","article-title":"Nanobody based dual specific CARs","volume":"19","author":"De Munter","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neo.2026.101375_bib0073","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1038\/s41551-024-01258-8","article-title":"Targeting overexpressed antigens in glioblastoma via CAR T cells with computationally designed high-affinity protein binders","volume":"8","author":"Xia","year":"2024","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.neo.2026.101375_bib0074","article-title":"CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression","volume":"13","author":"Arroyo-R\u00f3denas","year":"2025","journal-title":"J. ImmunOther ."},{"key":"10.1016\/j.neo.2026.101375_bib0075","doi-asserted-by":"crossref","first-page":"7622","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.neo.2026.101375_bib0076","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1302354","article-title":"Targeting colorectal cancer cells using AND-gated adaptor RevCAR T-cells","volume":"14","author":"Soto","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2026.101375_bib0077","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.iotech.2020.09.001","article-title":"Function and evolution of the prototypic CD28\u03b6 and 4-1BB\u03b6 chimeric antigen receptors","volume":"8","author":"Feucht","year":"2020","journal-title":"Immunooncol. Technol."},{"key":"10.1016\/j.neo.2026.101375_bib0078","first-page":"377","article-title":"Rationally designed approaches to augment CAR-T therapy for solid tumor treatment","volume":"33","author":"Zhu","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.neo.2026.101375_bib0079","article-title":"CAR-T cell signaling dynamics, rational design principles and artificial intelligence for next-generation chimeric antigen receptors","volume":"17","author":"Liu","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2026.101375_bib0080","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.neo.2026.101375_bib0081","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1126\/science.aba6527","article-title":"Designed protein logic to target cells with precise combinations of surface antigens","volume":"369","author":"Lajoie","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.neo.2026.101375_bib0082","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007426","article-title":"HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity","volume":"11","author":"Bassan","year":"2023","journal-title":"J. ImmunOther Cancer."},{"key":"10.1016\/j.neo.2026.101375_bib0083","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101375_bib0084","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.neo.2026.101375_bib0085","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2026.101375_bib0086","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-026-10906-9","article-title":"In vivo genome-wide CRISPR screens of human T cells in solid tumours","author":"Liu","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.neo.2026.101375_bib0087","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12943-023-01830-x","article-title":"Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer","volume":"22","author":"Chen","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.neo.2026.101375_bib0088","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001688","article-title":"Deletion of Cbl-b inhibits CD8(+) T-cell exhaustion and promotes CAR T-cell function","volume":"9","author":"Kumar","year":"2021","journal-title":"J. ImmunOther Cancer."},{"key":"10.1016\/j.neo.2026.101375_bib0089","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1002361","article-title":"Interleukin-15 and chemokine ligand 19 enhance cytotoxic effects of chimeric antigen receptor T cells using zebrafish xenograft model of gastric cancer","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2026.101375_bib0090","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2358590","article-title":"CXCL10 and IL15 co-expressing chimeric antigen receptor T cells enhance anti-tumor effects in gastric cancer by increasing cytotoxic effector cell accumulation and survival","volume":"13","author":"Nie","year":"2024","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.neo.2026.101375_bib0091","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12967-024-04982-6","article-title":"Combined therapy of CAR-IL-15\/IL-15R\u03b1-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer","volume":"22","author":"Ye","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.neo.2026.101375_bib0092","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1158\/1078-0432.CCR-25-3052","article-title":"Phase I trial of P-PSMA-101 CAR T cells in patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Slovin","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.neo.2026.101375_bib0093","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s00277-023-05227-0","article-title":"Functional validation of the RQR8 suicide \/marker gene in CD19 CAR-T cells and CLL1CAR-T cells","volume":"102","author":"Xiong","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.neo.2026.101375_bib0094","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2019-123018","article-title":"Allogeneic anti-CD19 CAR T cells manufactured from healthy donors provide a unique cellular product with distinct phenotypic characteristics compared to CAR T cells generated from patients with mature B cell malignancies","volume":"134","author":"Graham","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.neo.2026.101375_bib0095","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abq3010","article-title":"Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia","volume":"14","author":"Ottaviano","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neo.2026.101375_bib0096","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1182\/blood-2021-152985","article-title":"Clinical manufacture of FT819: use of a clonal multiplexed-engineered master induced pluripotent stem cell line to mass produce off-the-shelf CAR T-cell therapy","volume":"138","author":"Yuan","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.neo.2026.101375_bib0097","doi-asserted-by":"crossref","first-page":"6317","DOI":"10.1016\/j.cell.2025.07.046","article-title":"Glycan shielding enables TCR-sufficient allogeneic CAR-T therapy","volume":"188","author":"Wu","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.neo.2026.101375_bib0098","doi-asserted-by":"crossref","first-page":"998","DOI":"10.3390\/cancers17060998","article-title":"CAR-\u03b3\u03b4 T cells targeting Claudin18.2 show superior cytotoxicity against solid tumor compared to traditional CAR-\u03b1\u03b2 T cells","volume":"17","author":"Zhao","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.neo.2026.101375_bib0099","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1158\/2326-6066.CIR-22-0565","article-title":"Immunogenetic metabolomics reveals key enzymes that modulate CAR T-cell metabolism and function","volume":"11","author":"Renauer","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.neo.2026.101375_bib0100","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1007\/s00262-021-02891-x","article-title":"Simultaneously target of normal and stem cells-like gastric cancer cells via cisplatin and anti-CD133 CAR-T combination therapy","volume":"70","author":"Han","year":"2021","journal-title":"Cancer Immunol. Immunther."},{"key":"10.1016\/j.neo.2026.101375_bib0101","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70057","article-title":"Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas","volume":"14","author":"Mir","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.neo.2026.101375_bib0102","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122024","article-title":"Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models","volume":"331","author":"Wang","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.neo.2026.101375_bib0103","article-title":"Targeting wnt signaling in the tumor immune microenvironment to enhancing EpCAM CAR T-cell therapy","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neo.2026.101375_bib0104","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006343","article-title":"Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells against solid tumor","volume":"11","author":"Gao","year":"2023","journal-title":"J. ImmunOther Cancer."},{"key":"10.1016\/j.neo.2026.101375_bib0105","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12967-025-06276-x","article-title":"IDO1 inhibition enhances CLDN18.2-CAR-T cell therapy in gastrointestinal cancers by overcoming kynurenine-mediated metabolic suppression in the tumor microenvironment","volume":"23","author":"Wu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.neo.2026.101375_bib0106","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1111\/cas.15828","article-title":"Combination therapy of DKK1 inhibition and NKG2D chimeric antigen receptor T cells for the treatment of gastric cancer","volume":"114","author":"Zhang","year":"2023","journal-title":"Cancer Sci."},{"key":"10.1016\/j.neo.2026.101375_bib0107","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1605488","article-title":"Lentinan enhances CAR-T cell potency in solid tumors by optimizing T cell differentiation","volume":"16","author":"Niu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neo.2026.101375_bib0108","article-title":"Development of Nectin4\/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626001077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626001077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:18:46Z","timestamp":1793636326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558626001077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":108,"alternative-id":["S1476558626001077"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2026.101375","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering CAR-T cell therapies for digestive tract cancer: advances, challenges, and strategies to overcome tumor heterogeneity and immunosuppressive barriers","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2026.101375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101375"}}